Zynerba Pharmaceuticals Shares Owned By Insiders vs. Total Debt
| ZYNEDelisted Stock | USD 0.36 0.01 2.70% |
For Zynerba Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zynerba Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Zynerba Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Zynerba Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Zynerba Pharmaceuticals over time as well as its relative position and ranking within its peers.
Zynerba |
Zynerba Pharmaceuticals Total Debt vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Zynerba Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Zynerba Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Zynerba Pharmaceuticals is rated below average in shares owned by insiders category among its peers. It is rated below average in total debt category among its peers making up about 55,095 of Total Debt per Shares Owned By Insiders. Comparative valuation analysis is a catch-all technique that is used if you cannot value Zynerba Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Zynerba Total Debt vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Zynerba Pharmaceuticals |
| = | 6.07 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Zynerba Pharmaceuticals |
| = | 334.43 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Zynerba Total Debt vs Competition
Zynerba Pharmaceuticals is rated below average in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 2.45 Billion. Zynerba Pharmaceuticals adds roughly 334,425 in total debt claiming only tiny portion of equities under Health Care industry.
Zynerba Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Zynerba Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Zynerba Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Zynerba Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Zynerba Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Zynerba Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.
Zynerba Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Zynerba Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Zynerba Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Zynerba Pharmaceuticals' important profitability drivers and their relationship over time.
Use Zynerba Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zynerba Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zynerba Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Zynerba Pharmaceuticals Pair Trading
Zynerba Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Zynerba Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zynerba Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zynerba Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zynerba Pharmaceuticals to buy it.
The correlation of Zynerba Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zynerba Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zynerba Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zynerba Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Zynerba Pharmaceuticals position
In addition to having Zynerba Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Defence Thematic Idea Now
Aggressive Defence
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |